Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,784 total articles

Old National Bancorp Reports First Quarter 2026 Results

Old National Bancorp Reports First Quarter 2026 Results

Old National Bancorp reported strong Q1 2026 results including net income of $229.6 million and diluted EPS of $0.59, reflecting solid loan growth, improved capital ratios, and effective expense control. Key highlights include an 8.0% annualized loan growth, improved deposits, stable credit quality, and ongoing capital returns through share repurch…

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics reported encouraging Phase 1 clinical trial results for SAB-142, its fully human anti-thymocyte globulin immunotherapy aimed at type 1 diabetes (T1D). The trial demonstrated C-peptide preservation and improved glycemic control in adult T1D participants, with most showing a 'super responder' profile linked to T cell exhaustion. T…

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Inc. announced new preclinical data demonstrating that Plinabulin significantly improves both the anticancer efficacy and safety profile of leading antibody-drug conjugate (ADC) therapies. Presented at AACR 2026, the data show enhanced tumor response rates, longer survival, and reduced toxicities when Plinabulin is combined with ADCs w…

NeurAxis Expands Payer Coverage with Four New Medical Policies

NeurAxis Expands Payer Coverage with Four New Medical Policies

NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, announced that four additional health insurers have adopted medical policy coverage for its IB-Stim Percutaneous Electrical Nerve Field Stimulation (PENFS) device. This expansion brings approximately 1.25 million more covered lives across several U.S. states, en…

Lantronix to Report Fiscal 2026 Third Quarter Results on May 6, 2026

Lantronix to Report Fiscal 2026 Third Quarter Results on May 6, 2026

Lantronix Inc., a Nasdaq-listed leader in Edge AI and Industrial IoT solutions, announced it will report its fiscal third quarter 2026 financial results on May 6, 2026, followed by a management-hosted conference call and webcast. The company provides intelligent computing and secure connectivity solutions for mission-critical applications across se…

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

Nutriband Inc.'s CEO Gareth Sheridan appeared on the Jack Neel Podcast to discuss the ongoing US fentanyl crisis and present Nutriband's AVERSA™ technology, which aims to improve safety by preventing abuse and misuse of transdermal drug patches like fentanyl. The technology is patent-protected internationally and the company is developing an abuse-…

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Rafael Holdings, Inc. announced an exclusive licensing agreement with MIT for a patent covering cyclodextrin use in Alzheimer's patients carrying the ApoE4 gene variant. This expands the intellectual property portfolio for Trappsol® Cyclo™, which has shown promising preclinical effects on cholesterol transport, tau pathology reduction, and cognitiv…

Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat

Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat

Certara, Inc. announced an agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, aiming to sharpen focus and accelerate investments in its Model-Informed Drug Development (MIDD) and Clinical Intelligence platforms. The Regulatory and Medical Writing segment generated $50 million in revenue and $17 million…

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics announced encouraging preclinical results from multiple oncology programs at AACR 2026, demonstrating the potential of their targeted protein degradation pipeline. Key programs include the pan-mutant BRAF degrader NRX-0305, CBL-B intramolecular glue inhibitors (NX-1607), and Aurora Kinase A degrader NRX-4972. The data show enhanc…

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix, a biopharmaceutical company specializing in retina disease treatments, announced an Investor Day event scheduled for June 17, 2026 in New York City with virtual access available. The event will feature senior leadership and key opinion leaders discussing its pipeline including the Phase 3 trials of AXPAXLI for wet AMD and diabet…

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

Amneal Pharmaceuticals announced its agreement to acquire Kashiv BioSciences, creating a fully integrated global biosimilars platform positioned to capitalize on a $300 billion global biologics loss-of-exclusivity opportunity. The transaction will accelerate Amneal's growth, diversify its portfolio, and enhance its biosimilar pipeline. Additionally…

Lulus to Report First Quarter 2026 Results on May 13, 2026

Lulus to Report First Quarter 2026 Results on May 13, 2026

Lulu’s Fashion Lounge Holdings, a Nasdaq-listed women's clothing brand, will release its Q1 2026 financial results on May 13, 2026. The company will host a conference call and webcast for investors the same day. Lulu’s specializes in modern, feminine apparel at accessible prices and serves customers worldwide.

StoneX Announces Day-One Access to SHFE Nickel Futures

StoneX Announces Day-One Access to SHFE Nickel Futures

StoneX Group Inc. announced that it now provides its clients with day-one access to Nickel futures and options listed on the Shanghai Futures Exchange (SHFE) via the Overseas Intermediary route, following regulatory approval. This marks a significant development as SHFE contracts become accessible to international participants, enhancing StoneX's o…

Fortuna to release first quarter 2026 financial results on May 6, 2026; Conference call at 12 p.m. Eastern time on May 7, 2026

Fortuna to release first quarter 2026 financial results on May 6, 2026; Conference call at 12 p.m. Eastern time on May 7, 2026

Fortuna Mining Corp., a Canadian precious metals miner listed on the NYSE and TSX, announced it will release its Q1 2026 financial results on May 6, 2026, after market close. The company will hold a conference call on May 7, 2026, to discuss operational and financial performance, inviting analysts, investors, and media to participate. Fortuna opera…